For liver-related parameters, lean-MAFLD and overweight/obese-MAFLD patients had similar AST, Fibrosis-4 (FIB-4), NAFLD Fibrosis Score (NFS), Liver Stiffness Measurement (LSM) by Magnetic Resonance Elastography (MRE), but lower Controlled Attenuation Paramater (CAP) scores (MD – 16.21 (95% CI – 27.32 to – 5.10), p = 0.02), modestly lower LSM by Fibroscan® (MD – 0.55, 95% CI – 0.74 to 0.36), p < 0.01) and lower ALT (MD –7.17 (95% CI – 11.29 to – 3.04), p = 0.05) (Table 2). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.